Transcatheter aortic valve implantation (TAVI) has emerged as the treatment of choice for symptomatic severe aortic stenosis (AS) across the whole surgical risk spectrum.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Aortic Valve
May 1, 2025
Women with severe symptomatic aortic stenosis are underrepresented in clinical trials. The Randomized Research in Women All Comers with Aortic Stenosis (RHEIA) trial investigates the balance of benefits and risks of transcatheter aortic valve implantation (TAVI) compared to surgery in women.
April 24, 2025
The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years. In this new publication, the authors report the five-year outcomes of the Evolut Low Risk trial.
April 17, 2025
This study compared the perioperative and longitudinal risk-adjusted outcomes of patients aged 65 and older with severe aortic stenosis and concomitant coronary artery disease undergoing either coronary artery bypass grafting with surgical aortic valve replacement (CABG+SAVR) or percutaneous coronary intervention with transcatheter aortic valve repla
Low-Dose Warfarin With a Novel Mechanical Aortic Valve: Interim Registry Results at 5-Year Follow-Up
April 3, 2025
This study evaluated the safety of low-dose warfarin (target INR 1.8) combined with daily aspirin (75 100 mg) after On-X mechanical aortic valve implantation.
March 27, 2025
This study evaluated the long-term outcomes of the Ross procedure in neonates and infants with aortic valve pathology demonstrating good post-discharge survival and minimal need for reintervention.
January 30, 2025
This study evaluated long-term outcomes of bioprosthetic and mechanical aortic valve replacement (AVR) using data from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS-ACSD).
January 23, 2025
The authors evaluated the five-year outcomes in low-risk patients undergoing isolated surgical aortic valve replacement (SAVR) or SAVR with concomitant procedures within the randomized PARTNER 3 trial. In the PARTNER 3 trial, 454 patients with severe, symptomatic, tricuspid aortic stenosis (AS) underwent surgery and were followed for five years.
January 23, 2025
This study compared isolated primary bioprosthetic surgical aortic valve replacement (SAVR) with isolated redo surgical aortic valve replacement (rSAVR) due to structural valve deterioration (SVD).
January 23, 2025
In this article, the authors aimed to assess whether post-implant transcatheter aortic valve prosthesis multi-detector computed characteristics differ between patients with native tricuspid and bicuspid aortic valve stenosis, as well as the effect on valve performance and clinical outcomes.